{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reduction+in+Immunosuppression+Medication", "query": { "intervention": "Reduction in Immunosuppression Medication" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reduction+in+Immunosuppression+Medication&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T21:02:56.003Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06265584", "title": "Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Disorders" ], "interventions": [ { "name": "ATG dosing platform when combined with standard tacrolimus and mini methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 56, "start_date": "2025-04-08", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06265584" }, { "nct_id": "NCT02029638", "title": "BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "bone marrow transplant", "type": "BIOLOGICAL" }, { "name": "MESNA", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 4, "start_date": "2014-01-07", "completion_date": "2017-09-06", "has_results": true, "last_update_posted_date": "2018-09-24", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029638" }, { "nct_id": "NCT02474199", "title": "Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant Recipient", "Living Donor (of the Respective Liver Transplant Recipient)" ], "interventions": [ { "name": "darTregs", "type": "BIOLOGICAL" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Immunosuppression (IS) Withdrawal", "type": "DRUG" }, { "name": "Study Mandated Procedures", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2016-06-06", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02474199" }, { "nct_id": "NCT03577431", "title": "Liver Transplantation With Tregs at MGH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "arTreg-CSB", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 9, "start_date": "2019-03-29", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03577431" }, { "nct_id": "NCT06552169", "title": "REgulatory T Cell Therapy to Achieve Immunosuppression REduction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Arm 1: SOC (mTOR + CNI)", "type": "DRUG" }, { "name": "Arm 2A: TRACT/MONO mTOR", "type": "BIOLOGICAL" }, { "name": "Arm 2B: TRACT/MONO CNI", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Singulera Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2025-06-13", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06552169" }, { "nct_id": "NCT05077254", "title": "COVID Protection After Transplant-Immunosuppression Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Recipients", "Liver Transplant Recipients" ], "interventions": [ { "name": "Pfizer-BioNTech COVID-19 Vaccine 2023-2024", "type": "BIOLOGICAL" }, { "name": "Moderna COVID-19 Vaccine 2023-2024", "type": "BIOLOGICAL" }, { "name": "SOC IS Regimen", "type": "DRUG" }, { "name": "SOC IS Reduction", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-12-06", "completion_date": "2025-02-21", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 15, "location_summary": "San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077254" }, { "nct_id": "NCT00658333", "title": "A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Enteric-coated Mycophenolate Acid (EC-MPA)", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Placebo MMF", "type": "DRUG" }, { "name": "Placebo EC-MPA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2008-03", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2012-08-07", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658333" }, { "nct_id": "NCT02533180", "title": "Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Transplant", "Liver Transplantation" ], "interventions": [ { "name": "Immunosuppression withdrawal", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2015-12-15", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2023-09-14", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 7, "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02533180" }, { "nct_id": "NCT02711826", "title": "Treg Therapy in Subclinical Inflammation in Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplant", "Adult Living Donor Kidney Transplant Recipients", "Renal Transplant", "Living Kidney Donor" ], "interventions": [ { "name": "Polyclonal Regulatory T Cells", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Mycophenolic acid", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Biopsy, Kidney", "type": "PROCEDURE" }, { "name": "Blood Draw", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "IS regimen conversion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-09-20", "completion_date": "2023-08-04", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711826" }, { "nct_id": "NCT03654040", "title": "Liver Transplantation With Tregs at UCSF", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "arTreg", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2021-04-22", "completion_date": "2023-03-06", "has_results": true, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-09-22T21:02:56.003Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654040" } ] }